Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VX-017

Cell therapy · developed by VERTEX PHARMACEUTICALS INC / MA

Phase 3 Most advanced trial

VRTX Developer

1 Registered trials

What is VX-017?

VX-017 is a cell therapy infused into the hepatic portal vein, studied in type 1 diabetes mellitus and severe hypoglycemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy
Therapy area: Endocrine
Developer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04786262	Phase 3	Diabetes Mellitus, Type 1	Recruiting	VRTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1Impaired Hypoglycemic AwarenessSevere Hypoglycemia

More from VERTEX PHARMACEUTICALS INC / MA

Deutivacaftor FDA approved Elexacaftor FDA approved Exagamglogene Autotemcel FDA approved Ivacaftor FDA approved Suzetrigine FDA approved Tezacaftor FDA approved Vanzacaftor FDA approved Inaxaplin Phase 2/3 Povetacicept Phase 2/3 VX-118 Phase 1 VX-264 Phase 1/2 VX-272 Phase 1

Sources

ClinicalTrials.gov NCT04786262

Updated Oct 3, 2026. Something wrong or missing? Report it on the VRTX page.

Follow VRTX, the company behind VX-017

See VRTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

VRTX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z